Parkinson's Disease Neuroprotection Clinical Trial

帕金森病（PD）是第二常见的神经退行性疾病。虽然一些症状 尽管已经开发了多种治疗方法，但是还没有确定停止或减缓这种进行性疾病的治疗。用于 基于多种原因，我们认为开始一项或多项前瞻性临床试验 承诺代理人，以确定他们是否提供利益。本申请的目的是作为临床中心参与 一项关于神经保护剂的合作研究药物和方案将由NINDS规定。 UCSF在为PD受试者提供专科护理方面有着悠久的历史。UCSF帕金森病 临床与研究中心（PDCRC）参与了许多临床试验，以阐明神经系统 功能障碍的基础PD以及测试各种新的治疗PD。这项研究包括一些 行业申办的早期至晚期PD受试者治疗试验。一个庞大的、多样化的当地人口提供了 为临床研究提供可靠的受试者来源。加州大学旧金山分校PDCRC在评估，选择， 和以下PD受试者使其成为多中心、前瞻性试验的理想候选者， 神经保护剂治疗。 理想的神经保护治疗应该是有效的、便宜的、耐受性好的、安全的、易于管理的，并且 与普通药物的相互作用很少。在过去的十年里，许多关于人类和实验性的研究 动物已经证明了由小胶质细胞和许多炎症介导的局部免疫反应 细胞因子此外，几种PD动物模型已经证明抗炎药物可以干扰 与局部免疫反应，并可能保护多巴胺能神经元的功能。尽管新兴 了解帕金森病的发病机制可能为神经保护剂治疗提供一个替代的候选者，我们建议 抗炎药是治疗帕金森病的一种合理而实用的药物 神经保护试验。

Parkinson's disease (PD) is the second most common neurodegenerative disorder. While a number symptomatic therapies have been developed, no treatment has been identified that halts or slows this progressive disorder. For a number of reasons, we believe that it is appropriate to begin a prospective clinical trial of one or more of the more promising agents to determine whether they offer benefit. The aim of this application is to participate as a clinical center in a collaborative study of neuroprotective agents. The agents and protocol will be specified by NINDS. UCSF has a long history in providing subspecialty care for subjects with PD. The UCSF Parkinson's Disease Clinic & Research Center (PDCRC) has been involved in a number of clinical trials to elucidate the neurologic dysfunction underlying PD as well as testing a variety of novel treatments for PD. This research has included a number of industry sponsored treatment trials for subjects with early to advanced PD. A large diverse, local population provides a reliable source of motivated subjects for clinical research. The experience of the UCSF PDCRC in evaluating, selecting and following subjects with PD make it an ideal candidate for a multicenter, prospective trial of a potential neuroprotectant therapy. The ideal neuroprotective treatment should be effective, inexpensive, well tolerated, safe, easy to administer, and have few interactions with common medications. A number of studies over the last decade in humans and experimental animals have demonstrated a local immunologic response mediated by microglia and a number of inflammatory cytokines. Moreover, several animal models of PD have demonstrated that anti-inflammatory medications can interfere with the local immunologic response, and that they may preserve function of dopaminergic neurons. Although emerging understanding of the pathogenesis of PD may provide an alternative candidate for a neuroprotectant therapy, we propose that an anti-inflammatory medication would be a rational and practical candidate for the Parkinson's disease Neuroprotection Trial.